Beacon Financial Advisory LLC Reduces Holdings in Insmed Incorporated (NASDAQ:INSM)

Beacon Financial Advisory LLC decreased its holdings in Insmed Incorporated (NASDAQ:INSM) by 23.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,940 shares of the biopharmaceutical company’s stock after selling 2,735 shares during the quarter. Beacon Financial Advisory LLC’s holdings in Insmed were worth $617,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC increased its stake in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed during the fourth quarter worth $47,000. Exchange Traded Concepts LLC lifted its position in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Insmed by 2,348.8% in the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 1,879 shares during the period.

Insmed Stock Performance

Insmed stock opened at $81.44 on Thursday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The firm’s 50 day moving average price is $72.69 and its two-hundred day moving average price is $73.04. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $81.96.

Analyst Ratings Changes

Several equities research analysts have weighed in on INSM shares. JPMorgan Chase & Co. increased their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Insmed in a research note on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, Bank of America lifted their target price on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Insider Activity

In related news, insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the transaction, the insider now directly owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $69.91, for a total value of $1,310,812.50. Following the sale, the chief executive officer now owns 384,960 shares of the company’s stock, valued at $26,912,553.60. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 214,630 shares of company stock valued at $15,913,869 over the last three months. Insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.